Role of Co-crystals in the Pharmaceutical Development Continuum
Over the last ten years, the number publications, along with scientific conferences and workshops, outlining the advancement of design strategies, growing methods, analytical characterization techniques, and physicochemical property enhancements of co crystals has continued to increase significantly. Multi-component crystalline systems are not new to the pharmaceutical world, but only recently has the term ‘co-crystal’ been used in this field to describe materials containing two or more non-ionized components existing in one, independent crystalline lattice. Within the last decade solid-state researchers have focused on making co-crystals from pharmaceuticals, because they allow modifications to be introduced to the crystal structure of an active pharmaceutical ingredient, API (which in turn can alter its physical and chemical properties) without compromising its intended biological activity. This chapter will highlight and discuss the physical and chemical property improvements that have been achieved through co-crystalline materials of APIs, particularly focusing on stability, solubility, and bioavailability, and will attempt to put these activities within the context of the pharmaceutical development continuum.